![]() | |
Clinical data | |
---|---|
Trade names | Axumin |
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
License data |
|
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
Chemical and physical data | |
Formula | C5H818FNO2 |
Molar mass | 132.12g·mol−1 |
3D model (JSmol) | |
| |
|
Fluciclovine (18F), also known as anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid (anti-3[18F] FACBC), [3] [4] and sold under the brand name Axumin, is a diagnostic agent used for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated prostate specific antigen (PSA) levels. [5] [6]
Most imaging tests have not been able to localize recurrent prostate cancer when the PSA is mildly increased. [3] [5] Axumin scans were compared to [11C]-tagged choline PET scans, another FDA approved PET scan that can assist in this situation, and to biopsy results. [5] [7] Fluciclovine tagged PET scans appear to more sensitive than CT scans [8] and to [11C]-tagged choline PET scans. [9] [10]
Fluciclovine is a [18F]-tagged synthetic analog of the amino acid L-leucine. [11] [12] FACBC uptake by the tumor is related to functional activity of two amino acid transporters, [13] specifically sodium-dependent system ASC, with a lesser contribution by sodium-independent system L. [12] Although it is handled by the amino acid transporter system, it does not undergo terminally incorporative metabolism within the body. [12] The distribution of the tracer in the body differs from choline and FDG, as kidney uptake of FACBC is negligible, and no activity is found in the urinary tract. [12] [13] There is low native brain uptake compared to FDG, which may enhance detection of brain metastases [4] [12] or primary brain tumors. [12] The more intense native liver and pancreatic uptake seen with this agent would be expected to limit disease detection in those organs. [12] FACBC has a short synthesis time and a long half-life, which eliminate the need for an onsite cyclotron. [13]
Axumin is marketed by Blue Earth Diagnostics, Ltd., United Kingdom. [6]